Organovo (ONVO) said Tuesday that it has completed the sale of its farnesoid X receptor, or FXR, program to Eli Lilly (LLY).
The agreement was announced in February, with Organovo saying it will sell the FXR program for an upfront payment of $10 million and potential milestone payments of up to $50 million.
Eli Lilly has now acquired all commercial and intellectual property rights to the FXR program and will be responsible for its future clinical development.
Price: 2.92, Change: -0.07, Percent Change: -2.34
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.